Safe Step Act
Introduced September 19, 2025 · Last action September 19, 2025
Plain English Summary
This bill requires employer health plans and group health insurance to create a clear process allowing patients or their doctors to request exceptions to step therapy protocols—rules that force patients to try cheaper drugs first before getting approval for more expensive ones. If certain medical conditions are met (prior drugs failed, treatment delay could worsen the condition, the required drug causes harm, or the patient is stable on their current drug), the plan must approve the exception and cover the requested drug within 72 hours (or 24 hours in urgent cases) and for at least one year.
Who benefits
Patients enrolled in employer group health plans who need prescription drugs restricted by step therapy protocols, particularly those with prior treatment failures, contraindications to required drugs, or conditions where treatment delays risk serious harm. Prescribers (physicians and other clinicians) who gain authority to request exceptions on behalf of patients. Pharmaceutical manufacturers of brand-name and specialized drugs that step therapy protocols restrict, as faster exception approvals increase access and prescription volume.
Who pays / loses
Employer health plans and group health insurers, who must establish exception processes, respond to requests within tight timeframes, and ultimately cover more non-preferred (typically higher-cost) drugs. Pharmacy benefit managers (PBMs) contracted by plans, who will face increased administrative burden and must report data to plans. Plan sponsors (employers) who purchase group health coverage will face higher premium costs if exception approvals increase drug spending.
Funding & Lobbying Interests
Pharmaceutical companies manufacturing brand-name and specialty drugs stand to benefit directly from faster, more accessible step therapy exceptions, as step therapy protocols are cost-containment tools designed to limit their market share in favor of cheaper generics and preferred alternatives. Patient advocacy groups focused on rare diseases and chronic conditions typically support step therapy reform. The bill was introduced by Representatives Allen, McBath, Miller-Meeks, Ruiz, and Onder—a bipartisan group. PBMs and pharmacy chains that process prescriptions will see business volume changes depending on exception approval rates. Health insurance industry groups and employer coalitions generally oppose step therapy exceptions, as they increase drug costs.
Political Impact
Affected Groups
Approximately 160+ million Americans enrolled in employer-sponsored group health plans (the primary market for step therapy protocols). Patients with chronic, rare, or complex conditions disproportionately benefit, as step therapy most commonly restricts access to specialized medications. Prescribers (roughly 1 million licensed physicians in the U.S.) gain new tools to override plan restrictions. Self-funded employers (covering roughly 60% of employees nationally) and their plan administrators face direct administrative and cost impacts.
Political Subtext
Proponents argue step therapy improperly delays access to necessary medications, harms patients whose prior treatments failed, and puts insurance companies rather than doctors in control of prescribing decisions. They point to cases where step therapy protocols force patients to endure ineffective drugs or suffer preventable health deterioration. Critics from the insurance and employer benefits industries argue that step therapy is a legitimate cost-management tool that reduces unnecessary spending on expensive drugs and that the bill's 24-72 hour approval windows make clinical review impossible and will substantially increase drug costs. Employer coalitions warn premiums will rise. Non-partisan policy research shows step therapy reduces drug spending but also documents cases where it delays access to effective treatments; evidence on net health outcomes is mixed by condition and population. CBO has not scored this bill. The law reflects a value judgment that faster access to requested drugs outweighs cost containment through step therapy.
Real-World Stakes
If passed, millions of patients in employer plans will gain faster access to non-preferred drugs. Insurers will deny fewer step therapy requests under the defined circumstances, increasing prescription drug spending for plans. Employers will likely see premium increases, though the magnitude depends on approval rate increases. Prescribers will spend time completing exception request forms but gain authority to override step therapy denials. At the state level, step therapy exception laws exist in many states (e.g., Florida, Illinois, Georgia), and generally show that while exceptions increase drug access, the cost and health outcome impacts vary by condition. The 2018 Prescription Drug Addiction in the Healthcare system (PDAHS) report documented that state-level step therapy reforms increased approval rates but also led to higher out-of-pocket costs for some patients and increased overall drug spending. The annual reporting requirement will create the first systematic federal data on step therapy exception patterns across employer plans, filling a current data gap.
Sponsor
Sponsor information not available.
Vote Record
No recorded votes.
Campaign Finance — Primary Sponsor
No campaign finance data available yet.
501(c)(4) disclosure: Contributions from 501(c)(4) "dark money" organizations are not required to be publicly disclosed and are not reflected in the figures above. Data sourced from FEC public disclosure filings.
Community Discussion
Share this bill
Sign in to join the discussion.
No comments yet. Be the first.